Penumbra, Inc. (PEN)
USD 238.9
(-3.49%)
USD 238.9
(-3.49%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.05 Billion USD | 24.95% |
| 2022 | 847.13 Million USD | 13.32% |
| 2021 | 747.59 Million USD | 33.4% |
| 2020 | 560.41 Million USD | 2.38% |
| 2019 | 547.4 Million USD | 23.03% |
| 2018 | 444.93 Million USD | 33.31% |
| 2017 | 333.76 Million USD | 26.75% |
| 2016 | 263.31 Million USD | 41.5% |
| 2015 | 186.09 Million USD | 48.27% |
| 2014 | 125.51 Million USD | 41.26% |
| 2013 | 88.84 Million USD | 21.47% |
| 2012 | 73.14 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 278.65 Million USD | -2.12% |
| 2024 Q3 | 301.03 Million USD | 0.55% |
| 2024 Q2 | 299.4 Million USD | 7.45% |
| 2023 Q1 | 241.39 Million USD | 9.12% |
| 2023 Q2 | 261.49 Million USD | 8.33% |
| 2023 Q4 | 284.67 Million USD | 5.07% |
| 2023 Q3 | 270.94 Million USD | 3.61% |
| 2023 FY | 1.05 Billion USD | 24.95% |
| 2022 Q3 | 213.67 Million USD | 2.56% |
| 2022 Q4 | 221.21 Million USD | 3.53% |
| 2022 FY | 847.13 Million USD | 13.32% |
| 2022 Q1 | 203.89 Million USD | -0.06% |
| 2022 Q2 | 208.34 Million USD | 2.18% |
| 2021 Q1 | 169.2 Million USD | 1.38% |
| 2021 Q2 | 184.25 Million USD | 8.9% |
| 2021 Q3 | 190.11 Million USD | 3.18% |
| 2021 FY | 747.59 Million USD | 33.4% |
| 2021 Q4 | 204.01 Million USD | 7.31% |
| 2020 Q2 | 105.1 Million USD | -23.46% |
| 2020 FY | 560.41 Million USD | 2.38% |
| 2020 Q4 | 166.89 Million USD | 10.47% |
| 2020 Q3 | 151.07 Million USD | 43.73% |
| 2020 Q1 | 137.32 Million USD | -5.46% |
| 2019 Q4 | 145.26 Million USD | 4.13% |
| 2019 Q3 | 139.5 Million USD | 3.95% |
| 2019 Q2 | 134.2 Million USD | 4.49% |
| 2019 Q1 | 128.43 Million USD | 6.33% |
| 2019 FY | 547.4 Million USD | 23.03% |
| 2018 Q4 | 120.79 Million USD | 8.04% |
| 2018 Q2 | 109.63 Million USD | 6.75% |
| 2018 Q1 | 102.7 Million USD | 6.92% |
| 2018 FY | 444.93 Million USD | 33.31% |
| 2018 Q3 | 111.8 Million USD | 1.98% |
| 2017 FY | 333.76 Million USD | 26.75% |
| 2017 Q4 | 96.05 Million USD | 14.47% |
| 2017 Q3 | 83.91 Million USD | 4.12% |
| 2017 Q2 | 80.58 Million USD | 10.07% |
| 2017 Q1 | 73.21 Million USD | 0.15% |
| 2016 Q3 | 67.18 Million USD | 3.2% |
| 2016 Q1 | 57.91 Million USD | 6.44% |
| 2016 Q2 | 65.1 Million USD | 12.41% |
| 2016 Q4 | 73.1 Million USD | 8.81% |
| 2016 FY | 263.31 Million USD | 41.5% |
| 2015 Q1 | 38.95 Million USD | 10.02% |
| 2015 FY | 186.09 Million USD | 48.27% |
| 2015 Q4 | 54.41 Million USD | 7.93% |
| 2015 Q3 | 50.41 Million USD | 19.16% |
| 2015 Q2 | 42.31 Million USD | 8.62% |
| 2014 Q4 | 35.4 Million USD | 9.05% |
| 2014 Q2 | 31.48 Million USD | 20.32% |
| 2014 FY | 125.51 Million USD | 41.26% |
| 2014 Q3 | 32.46 Million USD | 3.13% |
| 2014 Q1 | 26.16 Million USD | 0.0% |
| 2013 FY | 88.84 Million USD | 21.47% |
| 2012 FY | 73.14 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Abbott Laboratories | 40.1 Billion USD | 97.361% |
| Allurion Technologies Inc. | 53.46 Million USD | -1879.767% |
| Artivion, Inc. | 354 Million USD | -199.014% |
| Avanos Medical, Inc. | 673.3 Million USD | -57.214% |
| Butterfly Network, Inc. | 65.9 Million USD | -1506.255% |
| Butterfly Network, Inc. | 65.9 Million USD | -1506.255% |
| Bio-Rad Laboratories, Inc. | 2.67 Billion USD | 60.374% |
| Boston Scientific Corporation | 14.24 Billion USD | 92.567% |
| Perspective Therapeutics, Inc. | 7.1 Million USD | -14800.366% |
| CONMED Corporation | 1.24 Billion USD | 14.701% |
| Edwards Lifesciences Corporation | 6 Billion USD | 82.372% |
| Paragon 28, Inc. | 216.38 Million USD | -389.176% |
| Glaukos Corporation | 314.71 Million USD | -236.347% |
| Globus Medical, Inc. | 1.56 Billion USD | 32.513% |
| Inspire Medical Systems, Inc. | 624.79 Million USD | -69.418% |
| Integer Holdings Corporation | 1.59 Billion USD | 33.705% |
| Medtronic plc | 32.36 Billion USD | 96.729% |
| Nevro Corp. | 425.17 Million USD | -148.962% |
| Owlet, Inc. | 54.01 Million USD | -1859.863% |
| Vicarious Surgical Inc. | - USD | -Infinity% |
| Smith & Nephew plc | 5.54 Billion USD | 80.924% |
| Sonendo, Inc. | 43.86 Million USD | -2313.136% |
| STERIS plc | 5.13 Billion USD | 79.401% |
| Stryker Corporation | 20.49 Billion USD | 94.836% |
| Vapotherm, Inc. | 68.66 Million USD | -1441.485% |
| Zimmer Biomet Holdings, Inc. | 7.39 Billion USD | 85.684% |